Supernus pockets $35M from new development pact

Rockville, MD-based Supernus has raised $35 million from an unnamed drug development partner. Supernus sold the future royalties from a new product it will help the partner develop. And that brings its haul of non-dilutive cash to $110 million for the last 17 months, according to a report in the Washington Business Journal.

"This is non-dilutive," Supernus CFO Rip Wilson tells the newspaper. "In this environment, with valuations for a lot of companies crushed, both public and private, that's a big deal. ... It was a strategic decision."

Last year, Supernus borrowed $75 million against its royalties from two therapies that rely on its technology. Much of the new money will be devoted to the late-stage clinical trials of two experimental epilepsy drugs now slated to begin by next year. An ADHD drug is in early-stage trials.

-  read the report from the Washington Business Journal

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.